Eli Lilly aims to be among top 20 pharma cos in India by 2020

Eli Lilly and Co India is looking to introduce more innovation-based products across five therapeutic segments, including diabetes, over the next six years as it aims to become one of the top 20 pharmaceutical companies in the country.
The company, which today launched an insulin delivery pen -- Humapen Savvio -- currently holds around 47th position in terms of revenues among pharma companies in India.
"We are committed to India and it's our aim to be among the top twenty pharma companies in India by 2020," Eli Lilly and Co India Managing Director Edgard A Olaizola told PTI.
The company lays maximum emphasis on its diabetes portfolio and would be introducing new products to cater to over 60 million patients in the country, he added.

"We expect to launch few products to cater to diabetes patients in the next three years. It is expected that the number of patients will cross 100 million by 2030," Olaizola said.
Besides the diabetes portfolio, the company has presence in osteoporosis, cardiovascular, oncology and growth hormones segments.

"Although diabetes remains our largest vertical, we would also be focusing on other areas, including oncology," Olaizola said.
As part of enhancing its diabetes product portfolio, the company today launched an insulin delivery pen, which the company plans to provide free to physicians while it will be available in pharmacies for Rs 1,000 per piece.

"The launch of HumaPen SAVVIO marks an important milestone for Lilly, reflecting our ongoing commitment to develop 'people-led' innovative solutions for diabetes," Olaizola said.
The pen, which can be used for six years to deliver insulin, will be co-promoted by Lilly-Boehringer Ingelheim alliance in India.
Eli Lilly and Boehringer Ingelheim had entered into an alliance in the field of diabetes in 2011.
"After the successful launch of Trajenta by the Lilly-Boehringer Ingelheim Alliance, this is another revolutionary product for the huge diabetes market in India," Boehringer Ingelheim India Managing Director Sharad Tyagi said.
In the first phase, the new product would be launched across six metros, including Delhi, Mumbai, Kolkata, Chennai.